DEEPECG4U: Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05829993
Collaborator
UMMISCO - Institute of Research for Development (IRD) (Other), CoreLab Banook (Other)
5,000
1
18
277.2

Study Details

Study Description

Brief Summary

The objective of this study is to prospectively validate in real life cohorts from various departments of the APHP our artificial intelligence (deep-learning) models allowing for :

  1. automatic measurement of various ECG quantitative features,

  2. identification and typing of LQT and risk of TdP.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Torsade-de-Pointes (TdP) are potentially fatal ventricular arrhythmias favored by a prolongation of ventricular repolarization (Long QT, LQT). The different types of existing LQT derive from the inhibition of cardiac potassium currents (IKr ; IKs) or the activation of a late sodium current (INaL). These alterations can be of congenital origin (3 types=>cLQT-1:IKs, cLQT-2:IKr, cLQT-3: INaL) or drug-induced (diLQT, via inhibition of IKr). More than 100 drugs have marketing authorization despite a risk of TdP because they have a favorable benefit/risk ratio (e.g. hydroxychloroquine).

    QTc, which represents the duration of ventricular repolarization (msec) and corresponds to the time between the beginning of the QRS and the end of the T-wave, corrected by heart rate, is prolonged in all LQT. Specific T-wave abnormalities as a function of the altered currents have been described and helps to discriminate cLQT/diLQT types. Thus, limiting the analysis of the ECG to that of the QTc is not very predictive because the information contained in an ECG is much richer and is not limited to the simple measurement of an interval.

    We have recently shown that analysis of ECGs using artificial intelligence (convolutional neural network, deep-learning) identifies elements of the ECG that are more discriminating in the prediction of the type of LQT and the risk of TdP, beyond of QTc. With these techniques, we have developed a model with probabilistic modules that predict the risk of TdP, identify the type of LQT (score ranging from 0 to 100%) and allow for the quantitative measurements of various common ECG parameters (including QTc, heart rate, PR and QRS).

    The objective of the project is to prospectively validate in real life cohorts from various departments of the APHP our model allowing for :

    1. automatic QTc measurement,

    2. identification and typing of LQT and risk of TdP.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    5000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias
    Anticipated Study Start Date :
    Apr 1, 2023
    Anticipated Primary Completion Date :
    Sep 1, 2024
    Anticipated Study Completion Date :
    Oct 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Cohort

    patients with a clinical indication to perform an ECG

    Outcome Measures

    Primary Outcome Measures

    1. Diagnostic property of an AI- deep learning model [Day 0]

      Evaluate the diagnostic properties (specificity, sensitivity, positive predictive value, negative predictive value) of a deep-learning quantitative QTc measurement model with a standardized and validated expert measurement to identify patients with very pathological QTc (≥500msec) within a population of hospitalized patients from various centres.

    Secondary Outcome Measures

    1. Identification of patients with congenital long QT [Day 0]

      Evaluate an AI-model for identification of patients with congenital long QT, and discriminate the type within a population of hospitalized patients

    2. Identification of patients with drug-induced acquired long QT [Day 0]

      Evaluate an AI-model for identification of patients with drug-induced acquired long QT

    3. Measurement of ECG quantitative features [Day 0]

      Evaluate an AI-model for measurements of QT, PR, QRS, heart rate and QTc.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age ≥ 18

    • Patients or subjects taken care in recruiting centres for which an ECG is indicated

    • No opposition to participation in the study

    Exclusion Criteria:
    • Medical contraindication for ECG

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre d'Investigation Clinique Paris-Est/Hôpital Pitié-Salpêtrière Paris France 75013

    Sponsors and Collaborators

    • Assistance Publique - Hôpitaux de Paris
    • UMMISCO - Institute of Research for Development (IRD)
    • CoreLab Banook

    Investigators

    • Principal Investigator: Joe-Elie SALEM, PU-PH, Assistance Publique - Hôpitaux de Paris

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Assistance Publique - Hôpitaux de Paris
    ClinicalTrials.gov Identifier:
    NCT05829993
    Other Study ID Numbers:
    • APHP211441
    • 2022-A01502-41
    First Posted:
    Apr 26, 2023
    Last Update Posted:
    Apr 26, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Assistance Publique - Hôpitaux de Paris
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 26, 2023